| “Democratizing” cancer care: City of Hope’s national enterprise model for delivering cancer care. J Schriber, AS Artz, A Purvis, JL Slack, JT Larsen, S Park, KF Tulipana, ... JCO Global Oncology 9 (Supplement_1), 103-103, 2023 | | 2023 |
| (CIBMTR Working Committee) Lymphoma AF Herrera, CS Sauter, M Shadman 2024 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2024 | | 2024 |
| (CIBMTR Working Committee) Lymphoma MA Kharfan-Dabaja, AF Herrera, CS Sauter 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| 2-year follow-up and high-risk subset analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-cel) in patients with refractory large B cell lymphoma SS Neelapu, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, O Oluwole, ... Biology of Blood and Marrow Transplantation 25 (3), S65, 2019 | 11 | 2019 |
| 2-Year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma SS Neelapu, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, ... Blood 132, 2967, 2018 | 25 | 2018 |
| 3-year analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) JC Chavez, M Dickinson, JL Munoz, ML Ulrickson, C Thieblemont, ... Blood 142, 894, 2023 | 4 | 2023 |
| 474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001 … D Davar, V Ribrag, C Sarkozy, E Garralda, HK Oberoi, A Mehta, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
| 8-Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) after Chimeric Antigen Receptor T-Cell Therapy Failure JC Zurko, J Ramdial, S Ahmed, A Szabo, L Iovino, M Shadman, ... Transplantation and cellular therapy 28 (3), S7-S9, 2022 | | 2022 |
| A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation MS Davids, HT Kim, C Costello, AF Herrera, FL Locke, RO Maegawa, ... Blood, The Journal of the American Society of Hematology 135 (24), 2182-2191, 2020 | 72 | 2020 |
| A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL RW Merryman, J Rhoades, K Xiong, K Antel, HH An, RA Redd, ... Blood 142, 527, 2023 | 1 | 2023 |
| A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis. J Timmerman, D Lavie, B Peter, GP Gregory, AF Herrera, L Minuk, ... Journal of Clinical Oncology 42 (16_suppl), 7055-7055, 2024 | | 2024 |
| A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis. J Timmerman, D Lavie, NA Johnson, A Avigdor, B Peter, C Andreadis, ... Journal of Clinical Oncology 42 (16_suppl), 7056-7056, 2024 | | 2024 |
| A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma NL Bartlett, AF Herrera, E Domingo-Domenech, A Mehta, A Forero-Torres, ... Blood, The Journal of the American Society of Hematology 136 (21), 2401-2409, 2020 | 110 | 2020 |
| A phase 2 multicenter trial of KTE-C19 (anti-CD19 CAR T cells) in patients with chemorefractory primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma … SS Neelapu, FL Locke, NL Bartlett, T Siddiqi, CA Jacobson, JR Westin, ... Blood 128 (22), 998, 2016 | 25 | 2016 |
| A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma MH Merrill, PB Dahi, RA Redd, MM McDonough, YB Chen, AS LaCasce, ... Blood 140 (Supplement 1), 1185-1187, 2022 | | 2022 |
| A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma MH Merrill, PB Dahi, RA Redd, MM McDonough, YB Chen, Z DeFilipp, ... Blood 142 (7), 621-628, 2023 | 3 | 2023 |
| A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma JL Crombie, AI Kim, NL Bartlett, RA Redd, V Patterson, C Carey, ... Blood 142, 1735, 2023 | | 2023 |
| A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) AF Herrera, MR Patel, JM Burke, RH Advani, BD Cheson, JP Sharman, ... Blood 130, 4129, 2017 | 11 | 2017 |
| A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) P Torka, S Kambhampati, A Muir, K Orand, L Smith, AF Herrera, L Lewis, ... Blood 138, 2433, 2021 | 2 | 2021 |
| A phase I/Ib study of nivolumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation (alloHCT) MS Davids, HT Kim, CL Costello, AF Herrera, FL Locke, RO Maegawa, ... Blood 132, 705, 2018 | 15 | 2018 |
